- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer
- Interventions
- CDX1307
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 16,113
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Foot Ulcer
- Interventions
- BR-AC, Standard Care
- Other
- Lead sponsor
- BioStem Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- San Francisco, California • Sylmar, California • Torrance, California + 8 more
- Conditions
- Alopecia Areata
- Interventions
- Daxdilimab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Hot Springs, Arkansas • Fountain Valley, California • Tampa, Florida + 3 more
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Behavioral Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer, Head and Neck Cancer, Melanoma
- Interventions
- Hello for Cancer game, Table Topics game
- Behavioral · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- High-Risk Melanoma
- Interventions
- gp100:209-217 (210M), Montanide ISA-51, Imiquimod
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 7 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma
- Interventions
- Nivolumab, Ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more
- Conditions
- HER2-positive Breast Cancer, Breast Cancer
- Interventions
- Paclitaxel, Trastuzumab, Pertuzumab, Pembrolizumab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Albuquerque, New Mexico + 2 more
- Conditions
- Molluscum Contagiosum
- Interventions
- Benzoyl peroxide, Adapalene Gel
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 1 Year to 14 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Breast Cancer
- Interventions
- questionnaires
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Lavior Diabetic Wound Gel, Smith & Nephew Solosite Gel Hydrogel Wound Dressing
- Drug
- Lead sponsor
- Lavior Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Male Breast Cancer, Mixed Adenocarcinoma of the Stomach, Ovarian Endometrioid Adenocarcinoma, Paget Disease of the Breast With Intraductal Carcinoma, Paget Disease of the Breast With Invasive Ductal Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Salivary Gland Adenocarcinoma, Stage II Malignant Testicular Germ Cell Tumor, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Gallbladder Cancer
- Interventions
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Xerostomia, Sjogren's Syndrome
- Interventions
- NGX267
- Drug
- Lead sponsor
- TorreyPines Therapeutics
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas
- Conditions
- Skin Laxity
- Interventions
- Venus Freeze Diamond Polar
- Device
- Lead sponsor
- Venus Concept
- Industry
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis
- Interventions
- Rehabilitation counseling
- Other
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
- Interventions
- PCR/PCR/LDR Strategy
- Genetic
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 21,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, erlotinib hydrochloride
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
- Interventions
- Questioners, STAR website
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,007 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Menkes Disease
- Interventions
- Long Term Follow-Up
- Drug
- Lead sponsor
- Sentynl Therapeutics, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Solana Beach, California
- Conditions
- Soft Tissue Infections
- Interventions
- daptomycin (up to 14 days)
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 12
- States / cities
- Torrance, California • Tampa, Florida • Augusta, Georgia + 9 more
- Conditions
- Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
- Interventions
- ALT-836 in combination with gemcitabine
- Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more
- Conditions
- Breast Cancer
- Interventions
- Biomarkers
- Other
- Lead sponsor
- Sentara Norfolk General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Newport News, Virginia
- Conditions
- Rectal Cancer, Breast Cancer, Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM)
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 2 more